Sexual adverse events
1 finding from 1 review
Serious adverse events: cardiovascular events · older adults with primary hypertension
Higher BP target (< 150‐160/95‐105 mmHg) showed no clear difference in cardiovascular serious adverse events compared with lower BP target (< 140/90 mmHg) (low certainty).
1 finding from 1 review
Adverse events ‐ total of adverse events (Skin irritation) · acute fractures in adults; included studies assessed effects in complete upper limb fractures (distal radius, clavicle, scaphoid,…
It is very uncertain whether low‐intensity pulsed ultrasound changes adverse events Reported as skin irritation compared with control (very low certainty).
1 finding from 1 review
Major adverse cardiac and cerebrovascular events · people with or without existing CVD, men and women
It is very uncertain whether higher polyunsaturated fatty acid (PUFA) changes major adverse cardiac and cerebrovascular events compared with lower PUFA (very low certainty).
1 finding from 1 review
Adverse events (not reported) · children with CP
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cardiovascular adverse events
Naftopidil showed no clear difference in cardiovascular adverse events compared with tamsulosin (alpha‐blocker) (low certainty).
1 finding from 1 review
Cardiovascular adverse events
Naftopidil showed no clear difference in cardiovascular adverse events compared with silodosin (alpha‐blocker) (low certainty).
1 finding from 1 review
Cardiovascular adverse events
Silodosin showed no clear difference in cardiovascular adverse events compared with naftopidil (low certainty).
1 finding from 1 review
Cardiovascular adverse events
Silodosin showed no clear difference in cardiovascular adverse events compared with alfuzosin (low certainty).
1 finding from 1 review
Cardiovascular adverse events
It is very uncertain whether silodosin changes cardiovascular adverse events compared with placebo (very low certainty).
1 finding from 1 review
Cardiovascular adverse events
Silodosin showed no clear difference in cardiovascular adverse events compared with tamsulosin (low certainty).
1 finding from 1 review
Cardiovascular adverse events
1 finding from 1 review
Cardiovascular adverse events
1 finding from 1 review
Withdrawals due to adverse events · participants with normal or abnormal lipid profiles
It is very uncertain whether all doses of cerivastatin changes withdrawals due to adverse events compared with placebo (very low certainty).
1 finding from 1 review
Intervention not reported
Adverse events: superficial infection · adults with open long bone fractures; study in the review included only Gustilo II open tibia fractures
It is very uncertain whether the intervention changes adverse events: superficial infection (very low certainty).
1 finding from 1 review
Intervention not reported
Incidence of adverse events ‐ overall · children with HIV infection aged 12 years and under
The intervention showed no clear difference in incidence of adverse events ‐ overall (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events
It is very uncertain whether naftopidil changes treatment withdrawals due to adverse events compared with eviprostat (phytotherapy) (very low certainty).
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review
Discontinuation of medication due to adverse events · people with diabetes and CKD
1 finding from 1 review